Endocannabinoid System Research: Trauma, Sleep & Cannabis Use
Pre-trauma insomnia substance use risk is a significant factor in predicting alcohol and cannabis use following trauma. This research highlights the importance of screening for sleep disturbances in trauma survivors. Addressing pre-trauma insomnia…
Endocannabinoid System & Adolescent Health: 15-Year REAL 2.0 Study
This 15-year REAL 2.0 study highlights endocannabinoid system adolescent health research focusing on eating disorders and mental health outcomes. It tracks youth into adulthood to understand psychosocial risk factors. The findings emphasize early…
Clinical Evidence on Cannabinoids in PTSD and Substance Use
Cannabinoids and PTSD clinical evidence indicate that trauma-focused treatments benefit patients with co-occurring substance use disorders. Cannabis use does not diminish the effectiveness of evidence-based PTSD care. Clinicians should consider this…
Cannabinoid Clinical Trials: Full-Spectrum Cannabis for Back Pain
This phase 3 trial evaluated the full-spectrum cannabis extract for chronic low back pain in 820 adults. The study showed pain reduction and sustained benefits over 12 months. Full-spectrum cannabis extract offers a promising option for patients with…
Research on Cannabis Use and Behavioral Outcomes in Children with ASD
Peripregnancy cannabis exposure behavioral outcomes show varied effects on children with and without ASD symptoms. This research highlights differences in behavioral and developmental associations. Understanding these outcomes is crucial for counseling…
Endocannabinoid System & GLP-1 Mental Health Evidence
GLP-1 receptor agonists mental health evidence suggests these drugs may influence psychiatric disorder risks. Genetic studies indicate potential benefits for schizophrenia. Patients should discuss mental health implications with clinicians.
Cannabinoid Clinical Trials: Teen Cannabis Intervention Study
This study evaluates a rebuttal-based social norms-tailored cannabis intervention designed to improve prevention messaging for at-risk adolescents. Personalized approaches challenge negative reactions to standard cannabis messages. Findings support…
Prevalence of Schizophrenia Spectrum and Bipolar Disorder Among Cannabis Induced Psychosis Patients
Cannabis induced psychosis risk prevalence clinical insights reveal that a significant portion of patients develop schizophrenia spectrum or bipolar disorder. Early identification and monitoring are essential for managing this risk. Understanding…
Endocannabinoid System Research: Cannabis in HIV Care
Digital therapeutics HIV smoking cessation research shows strong feasibility and acceptability among people living with HIV. This approach offers scalable cessation tools for this high-risk population. Tobacco use remains a leading cause of illness and…
Cannabidiol for Lennox-Gastaut: Cannabinoid Clinical Trials
Clinically meaningful reduction in drop seizures has been observed in Lennox-Gastaut syndrome patients treated with cannabidiol. Clinical trials show that even reductions below 50% can improve patient quality of life. Caregiver-reported outcomes align…